Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

Nele Claes; Tessa Dhaeze; Judith Fraussen; Bieke Broux; Bart Van Wijmeersch; Piet Stinissen; Raymond Hupperts; Niels Hellings; Veerle Somers

doi:10.1371/journal.pone.0111115

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

Nele Claes, Tessa Dhaeze, Judith Fraussen, Bieke Broux, Bart Van Wijmeersch, Piet Stinissen, Raymond Hupperts, Niels Hellings, Veerle Somers^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p

Original language	English
Article number	e111115
Journal	PLOS ONE
Volume	9
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0111115
Publication status	Published - 31 Oct 2014

Access to Document

10.1371/journal.pone.0111115Licence: CC BY

Cite this

@article{5dc2edb0a4474b8fbabece08ee21ffa5,

title = "Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study",

abstract = "Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p",

author = "Nele Claes and Tessa Dhaeze and Judith Fraussen and Bieke Broux and {Van Wijmeersch}, Bart and Piet Stinissen and Raymond Hupperts and Niels Hellings and Veerle Somers",

year = "2014",

month = oct,

day = "31",

doi = "10.1371/journal.pone.0111115",

language = "English",

volume = "9",

journal = "PLOS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

AU - Claes, Nele

AU - Dhaeze, Tessa

AU - Fraussen, Judith

AU - Broux, Bieke

AU - Van Wijmeersch, Bart

AU - Stinissen, Piet

AU - Hupperts, Raymond

AU - Hellings, Niels

AU - Somers, Veerle

PY - 2014/10/31

Y1 - 2014/10/31

N2 - Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p

AB - Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimod-treated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p

U2 - 10.1371/journal.pone.0111115

DO - 10.1371/journal.pone.0111115

M3 - Article

C2 - 25360562

SN - 1932-6203

VL - 9

JO - PLOS ONE

JF - PLOS ONE

IS - 10

M1 - e111115

ER -